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During the recent years, multiple studies demonstrated that C-peptide is not an inert peptide, but exerts important physiological
eﬀects. C-peptide binds to cell membranes, stimulates the Na,K-ATPase and the endothelial nitric oxide (NO) synthase. Moreover,
there is evidence that C-peptide decreases glomerular hyperﬁltration and increases glucose utilisation. Nevertheless, there is still
limited knowledge concerning mechanisms leading to an increased glucose utilisation either in rats or in humans. The aim of this
paper is to give an overview over the published studies regarding C-peptide and glucose metabolism from in vitro studies to longer
lasting studies in humans.
Copyright © 2008 B. Wilhelm et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. IN VITRO STUDIES
Z i e r a t he ta l .[ 1] showed that physiological concentrations
of human C-peptide stimulate glucose transport in human
skeletal muscle in a dose-dependent manner. In order to elu-
cidate the mechanisms by which C-peptide stimulates glu-
cose transport in human skeletal muscle, they investigated
the interaction between C-peptide and insulin binding to re-
ceptors, the potential role of C-peptide in activating the re-
ceptor tyrosine kinase, the inﬂuence of counter-regulatory
hormones on the C-peptide activation of the glucose trans-
port, and the eﬀect of C-peptide in glucose transportation
in skeletal muscle from patients with insulin-dependent dia-
b e t e sm e l l i t u s[ 2]. They demonstrated that C-peptide partly
shares a common pathway with insulin in stimulating skele-
tal muscle glucose transportation as simultaneous exposure
of maximal concentrations of insulin and C-peptide did not
result in an additive eﬀect of 3-o-methylglucose transport.
C-peptide did not alter the binding of insulin to the insulin
receptor nor was shown to have a speciﬁc binding to muscle
crudemembranes.C-peptidestimulatesglucosetransportby
mechanism independent of insulin receptor and tyrosine ki-
nase activity and in contrast to insulin, catecholamines did
not reveal a counter-regulatory eﬀect on the C-peptide me-
diated glucose transport. Under in vitro conditions, a stimu-
lation of glucose transportation could be also demonstrated
bypatientswithinsulin-dependentdiabetesmellitus.Despite
chronic deprivation of C-peptide in vitro, exposure of skele-
tal muscle strips from patients with insulin-dependent dia-
betes mellitus to a physiological concentration of C-peptide
increased the glucose utilisation measured by an augmented
3-o-methylglucose transport [2]. In vitro studies with iso-
lated mouse muscle showed that C-peptide did not stimulate
glycogen synthesis in isolated mouse muscle [3].
2. ANIMAL STUDIES
In 1983 it has been demonstrated that in alloxan-treated rats,
supra-physiololgical concentrations of C-peptide increased
and prolonged the hypoglygemic eﬀect of exogenous insulin
on whole body glucose uptake [4]. As glucose transport can
be stimulated by NO [5, 6], the aim of an euglycemic clamp
study in streptozotocin-induced diabetes rats was to exam-
ine whether C-peptide in physiological concentrations in-
creases whole body glucose utilisation and whether such an
eﬀect is diminished by an NO synthase inhibitor. Physio-
logical concentrations of homologous rat C-peptide I or II
augmented signiﬁcantly glucose disposal rate (GDR) by 80–
90%andmetabolicclearancerate(MCR)forglucoseby100–
125% in diabetic rats, whereas no eﬀects could be detected
in healthy control rats. A further increase in C-peptide con-
centrations did not let to further eﬀects on GDR or MCR
[7]. L-NMMA, a known inhibitor of NO-synthase, was able
to block about 85% of the C-peptide-induced increase in2 Experimental Diabetes Research
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Figure 1: C-peptide levels in healthy controls and patients with di-
abetes type 1 during the euglycemic clamp.
GDR. These results suggest that a major proportion of the
C-peptide stimulation of glucose utilisation is mediated by
NO [7].
Moreover, it could be shown that C-terminal fragments,
butnotfragmentsfromthemiddlesegmentofC-peptide,are
as eﬀective as the full-length peptide in stimulating whole-
body glucose turnover in streptozotocin-induced diabetes
rats [8].
3. SHORT-TERM HUMAN STUDIES
During a euglygemic clamp study in 11 patients with type 1
diabetes mellitus C-peptide was infused in two periods over
60 minutes in a concentration of 5 and 30 pmol/kg/min and
compared with 10 patients who received saline infusion. Af-
ter infusion of low-dose C-peptide, whole body glucose util-
isation rose by approximately 25% (P < .05), whereas no
changes in the saline group were detected. The high-dose
C-peptide infusion given to 7 of the 11 patients resulted in
a small further increase of about 15% (P < .05) in glucose
utilisation [9].
Forearm uptake of glucose after a 5-minute rhythmic
dynamic exercise with a handergometer increased signiﬁ-
cantly after C-Peptide infusion (−4.8 ± 3.1v e r s u s1 3 .6 ±
3.2umol·min−1100mL−1) in patients with diabetes melli-
tus [10]. We investigated in our study with 13 patients with
type 1 diabetes mellitus and 13 healthy control glucose util-
isation after administration of C-peptide (8pgmol/kg/body
weight/min)over2hoursduringaneuglycemicclampproce-
dure with either a high-dose (1.0Ul/kg body weight/min) or
a low-dose insulin infusion (0.25mU/kg body weight/min).
The C-peptide levels reached are shown in Figure 1.A f t e r
C-peptide infusion, glucose utilisation increased in patients
with diabetes mellitus (51.5 ± 25.6v e r s u s7 4 .51 ± 22.93g)
and healthy controls (74.91 ± 22.01 versus 99.38 ± 24.24g)
0
200
400
600
800
1000
1200
C D C+CD+C C D C+C D+C
Insulin 0.25mU/kg−1/min−1 Insulin 1mU/kg−1/min−1
#
∗
∗
#
#∗
∗ P<. 05 C versus D
# P<. 05 C-peptide versus control
Figure 2: Glucose utilisation in g during an euglygemic clamp with
low and high insulin concentrations in healthy controls (C), Dia-
betes mellitus type 1 and after administration of C-peptide (C+C)
and (D+C).
statistically signiﬁcant (P < .001) during high-dose insulin
infusion and from 16.31 ± 13.34 to 18.8 ± 16.2g in the dia-
betic patients and from 20.74 ± 9.96 to 35.8 ± 13.5g in the
healthy controls, the results are given in Figure 2 [11]. In a
recent study [12], it has been discussed that C-peptide might
increase the bioavailability of insulin by promoting the dis-
aggregation of hexameric insulin. The combined injection of
insulin and C-peptide required a greater amount and longer
duration of glucose than insulin alone in patients with di-
abetes type 1. In another setting, the same group applied
insulin and C-peptide in the same and in two separate de-
pots and found that the reduction in plasma glucose was sig-
niﬁcantly faster when administered in the same depot. The
amount of glucose that has to be infused in order to avoid a
hypoglycaemia was 129% (P < .01) by administration in the
same depot.
4. LONG-TERM HUMAN STUDIES
In a randomized, double-blind study 18 patients with type 1
diabetes received either regular insulin mixed with equimo-
lar amounts of biosynthetic human C-peptide or insulin
alone for 1 month as subcutaneous infusions using an in-
sulin pump. At the end of the study, fructosamine levels
decreased by about 16% from 3.8 ± 0.3t o3 .2 ± 0.1( P <
.05) mmol/L and HbA1c by about 10% from 8.0 ± 0.7% to
7.3 ± 0.5% (P < .05%). Fasting blood glucose tended to be
lower in the insulin and C-peptide treated group (NS). No
statistically signiﬁcant changes could be demonstrated in the
insulin group [13].
5. DISCUSSION
C-peptide in nanomolar concentrations binds speciﬁcally to
cell membranes, assumable by a G-protein-coupled receptor.
After activation of a Ca (2+)- and MAP Kinase-dependent
pathway, the Na,K-ATPase and the endothelial nitric oxide
synthase are stimulated, resulting in an increase of nitric ox-
ide [14]. Increased local release of nitric oxide by C-peptide,
resulting in an increased subcutaneous blood ﬂow, mightB. Wilhelm et al. 3
enhance insulin absorption and therefore glucose utilisation
[15].
Several studies as cited above have shown that C-peptide
increases glucose utilisation either in vitro or in vivo. The
eﬀect seems to be a consequence of the stimulation of glu-
cose transport in the skeletal muscle, independent of the
insulin receptor or the thyrosine kinase activity, but medi-
ated through nitric oxide [7]. When C-peptide concentra-
tions are increased above the physiological range, no further
stimulation of glucose utilisation can be demonstrated [7].
This might be explained by the hypothesis that C-peptide
receptors on cell membranes are relatively few and show
high-aﬃnity binding, thereby reaching saturation at low C-
peptide concentrations [15].
In conclusion, recent studies have demonstrated that C-
peptide is not an inert peptide, but a biologically active sub-
stancewhichhasbesidesothereﬀectsregulatoryinﬂuenceon
glucosemetabolism.ButstillmanymechanismsofC-peptide
action have to be resolved.
Longer lasting studies are needed in order to evaluate
continuing improvement of glucose utilisation in patients
with type 1 diabetes.
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